Who are Patent clopidogrel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Acetylsalicylic Acid + clopidogrel, Group P+T, clopidogrel (SR25990C), Aspirin and clopidogrel / Prasugrel, enoxaparin + clopidogrel + aspirin, ticagrelor + ASA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/patent-clopidogrel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Patent clopidogrel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Patent clopidogrel (Patent clopidogrel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist / Thienopyridine antiplatelet agent. Area: Cardiovascular.

marketed P2Y12 receptor antagonist / Thienopyridine antiplatelet agent P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Patent clopidogrel (Patent clopidogrel) — Hospital Central San Luis Potosi, Mexico. Clopidogrel inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Patent clopidogrel TARGET	Patent clopidogrel	Hospital Central San Luis Potosi, Mexico	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
Acetylsalicylic Acid + clopidogrel	Acetylsalicylic Acid + clopidogrel	Hospital Universitari Vall d'Hebron Research Institute	marketed	Dual antiplatelet agent	Cyclooxygenase-1 (COX-1) and P2Y12 receptor
Group P+T	Group P+T	Huazhong University of Science and Technology	marketed	P2Y12 inhibitor	P2Y12 receptor
clopidogrel (SR25990C)	clopidogrel (SR25990C)	Sanofi	marketed	P2Y12 receptor antagonist (thienopyridine)	P2Y12 receptor
Aspirin and clopidogrel / Prasugrel	Aspirin and clopidogrel / Prasugrel	Assistance Publique - Hôpitaux de Paris	marketed	Antiplatelet agent (dual therapy combination)	COX-1 (aspirin); P2Y12 receptor (clopidogrel/prasugrel)
enoxaparin + clopidogrel + aspirin	enoxaparin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Anticoagulant + antiplatelet combination	Factor Xa, Factor IIa, P2Y12 receptor, cyclooxygenase
ticagrelor + ASA	ticagrelor + ASA	Peking University Third Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist / Thienopyridine antiplatelet agent class)

Azienda Policlinico Umberto I · 1 drug in this class
Hospital Central San Luis Potosi, Mexico · 1 drug in this class
Sanofi · 1 drug in this class
Seung-Jung Park · 1 drug in this class
Stiftung Institut fuer Herzinfarktforschung · 1 drug in this class
US Department of Veterans Affairs · 1 drug in this class
University of Pecs · 1 drug in this class
VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Patent clopidogrel — Competitive Intelligence Brief. https://druglandscape.com/ci/patent-clopidogrel. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing